Skip to main content

CORRECTION

Transpl Int, 05 January 2023
Volume 35 - 2022 | https://doi.org/10.3389/ti.2022.11073

Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

Marina Lopez-Martinez,Marina Lopez-Martinez1,2Irina Torres,Irina Torres1,2Sheila Bermejo,Sheila Bermejo1,2Francesc Moreso, Francesc Moreso1,2*Clara Garcia-Carro,Clara Garcia-Carro3,4Ander Vergara,Ander Vergara1,2Natalia Ramos,Natalia Ramos1,2Manel Perello,Manel Perello1,2Alejandra Gabaldon,Alejandra Gabaldon2,5M. Antonieta Azancot,M. Antonieta Azancot1,2Monica Bolufer,Monica Bolufer1,2Nestor Toapanta,Nestor Toapanta1,2Oriol Bestard,Oriol Bestard1,2Irene Agraz-Pamplona,&#x;Irene Agraz-Pamplona1,2†Maria Jose Soler, &#x;Maria Jose Soler1,2*†
  • 1Department of Nephrology, Vall d’Hebron University Hospital, Barcelona, Spain
  • 2Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), Vall d’Hebron University Hospital, Barcelona, Spain
  • 3Department of Nephrology, San Carlos Clinical University Hospital, Madrid, Spain
  • 4Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), San Carlos Clinical University Hospital, Madrid, Spain
  • 5Department of Pathology, Vall d’Hebron University Hospital, Barcelona, Spain

A Corrigendum on
Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

by Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I and Soler MJ (2022). Transpl Int. 35:10693. doi: 10.3389/ti.2022.10693

In the original article, there was a mistake in Table 1 as published. Since publication, it has been noticed that the rows “BMI (Kg/m2)” and “LDL (mg/dl)” incorrectly contained repeated data. The corrected version of Table 1 is shown below.

TABLE 1
www.frontiersin.org

TABLE 1. Change from baseline of analytical parameters.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: IgA nephropathy, IgAN recurrence in transplant kidney, proteinuria reduction, TRF-budesonide, CKD progression

Citation: Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I and Soler MJ (2023) Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. Transpl Int 35:11073. doi: 10.3389/ti.2022.11073

Received: 22 November 2022; Accepted: 07 December 2022;
Published: 05 January 2023.

Copyright © 2023 Lopez-Martinez, Torres, Bermejo, Moreso, Garcia-Carro, Vergara, Ramos, Perello, Gabaldon, Azancot, Bolufer, Toapanta, Bestard, Agraz-Pamplona and Soler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Francesc Moreso, fjmoreso@vhebron.net; Maria Jose Soler, mjsoler01@gmail.com

†These authors share senior authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.